+7 (701) 759 90 19
USD 428.71 EUR 519.12
RUB 5.79 CNY 66.61
News

China approves new COVID-19 vaccine for clinical trials

11 April 2021 10:27
Share in:
China approves new COVID-19 vaccine for clinical trials

BEIJING. KAZINFORM A new COVID-19 vaccine developed by China's Sinopharm has recently been approved for clinical trials.

Related news
COVID-19: Aktobe and Almaty regions move to ‘red zone’ More than 677,000 COVID-19 infections detected worldwide over past 24 hours COVID-19-like pneumonia: 118 cases, 85 recoveries

The new recombinant COVID-19 vaccine, developed by the National Vaccine & Serum Institute, a R&D center of Sinopharm's bioscience subsidiary the China National Biotec Group (CNBG), got approval from the National Medical Products Administration on Friday, the CNBG said on its official Weibo account on Saturday.

The vaccine is based on the structural features of the receptor binding domain (RBD) on the virus' spike protein (S-protein). It uses genetic engineering to grow harmless copies of the virus S-protein to induce neutralizing antibodies, Xinhua reports.

The company said that recombinant vaccine technology is mature and suitable for large-scale production. The production does not require facilities with high biosafety levels since the process does not involve live viruses.

The recombinant vaccine is the company's third COVID-19 vaccine. Last December, an inactivated vaccine developed by the Beijing Biological Products Institute Co., Ltd. under CNBG became the first Chinese COVID-19 vaccine to have conditional marketing authorization.



Share in:
Related news
Read also
+7
Send
Employees online
Editor
Nurmaganbetova Zhanna
Nurmaganbetova Zhanna
954-048
Editor
Kudrenok Tatyana
Kudrenok Tatyana
954-048
Editor
Seilkhanov Adlet
Seilkhanov Adlet
954-048

Archive